Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
U32 CAR-T(Shanghai Unicar-Therapy Bio-medicine Technology) in Acute Myeloid Leukemia: NCT07036250 Clinical Landscape Report 2026
15 October 2026
NCT07036250 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avapritinib in Acute Myeloid Leukemia: NCT07028073 Clinical Landscape Report 2026
15 October 2026
NCT07028073 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CP-383 in Metastatic Solid Tumor: NCT07030257 Clinical Landscape Report 2026
15 October 2026
NCT07030257 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologous Tumor-infiltrating Lymphocyte(Samsung Medical Center) in Refractory Melanoma: NCT07028008 Clinical Landscape Report 2026
15 October 2026
NCT07028008 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA/GPRC5D CAR-T cells(Essen Biotech) in Relapse multiple myeloma: NCT07032129 Clinical Landscape Report 2026
15 October 2026
NCT07032129 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KJ-C2219 in Lupus Nephritis: NCT07031713 Clinical Landscape Report 2026
15 October 2026
NCT07031713 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Teclistamab in Relapse multiple myeloma: NCT07030517 Clinical Landscape Report 2026
15 October 2026
NCT07030517 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cirtuvivint in Locally Advanced Soft Tissue Sarcoma: NCT07032285 Clinical Landscape Report 2026
15 October 2026
NCT07032285 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Efgitasialase alfa in Idiopathic Membranous Glomerulonephritis: NCT07038382 Clinical Landscape Report 2026
15 October 2026
NCT07038382 clinical landscape for Idiopathic Membranous Glomerulonephritis: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Talquetamab in Relapse multiple myeloma: NCT07032714 Clinical Landscape Report 2026
15 October 2026
NCT07032714 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07038447 Clinical Landscape Report 2026
15 October 2026
NCT07038447 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
OPM-101 in Locally Advanced Melanoma: NCT07040436 Clinical Landscape Report 2026
15 October 2026
NCT07040436 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.